Atlanta-based biotech company expands with addition of renowned Duke University School of Medicine and Health System respiratory and critical care expert.
October 5, 2018, Atlanta, GA – VERO Biotech LLC, a biopharmaceutical company focused on the design, development and commercialization of next generation inhaled nitric oxide (NO), today announced the appointment of Michael Gentile, MBA, RRT, FAARC, FCCM, as Vice President of Medical Affairs. Mr. Gentile joins VERO Biotech from Duke University School of Medicine and Health System in Durham, NC, and brings to VERO over 30 years of clinical practice, clinical research, teaching, and leadership. He has served in key positions for societies such as AARC, SCCM, ACCP, and ACHE.
Mr. Gentile will be responsible for development of hospital education, clinical development, clinical operations, and data analysis and will contribute his expertise to solution development.
“Michael is an outstanding addition to VERO’s senior management team. He brings a wealth of practical knowledge and experience to our company. We consider Michael’s addition an endorsement of VERO’s commitment to providing valuable solutions in the highly complex acute care hospital setting,”
said Brent Furse, President and CEO at VERO Biotech. “Mike is highly respected and well recognized in the Respiratory and Critical Care communities.”
“I am excited to be part of the VERO Biotech team. My entire career has been spent seeking solutions for patients and clinicians, and I look forward to continuing those efforts with VERO,” said Mr. Gentile.
About VERO Biotech
VERO Biotech is a biopharmaceutical company focused on the design, development and commercialization of next generation inhaled nitric oxide (NO) delivery systems to address unmet medical needs of patients with cardiopulmonary conditions.